Phaseline

Companies › Beijing Suncadia Pharmaceuticals

Beijing Suncadia Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SHR-1918
APOB mRNA antisense oligonucleotide
APOBPhase 3Hypertriglyceridemia; Hyperlipidemia; HypercholesterolemiaMar 2027
HRS-4029–Phase 2Acute Ischemic StrokeApr 2027
HRS8179 injection–Phase 2Severe Cerebral Edema Following Large Hemispheric InfarctionJun 2027
SHR-2906 Injection–Phase 1ObesityDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07280936SHR-2906 InjectionPhase 1ObesityMetabolic and endocrineDec 2026
NCT07349615SHR-1918Phase 3HypertriglyceridemiaMetabolic and endocrineMar 2027
NCT07739160HRS-4029Phase 2Acute Ischemic StrokeNeurologyApr 2027
NCT06732648HRS8179 injectionPhase 2Severe Cerebral Edema Following Large Hemispheric InfarctionNeurologyJun 2027
NCT07230730SHR-1918Phase 3HyperlipidemiaMetabolic and endocrineOct 2027
NCT07404553SHR-1918Phase 2HypercholesterolemiaMetabolic and endocrineJul 2028

Targets

APOB (1)

Companies with the same targets

Alnylam Pharmaceuticals Vir Biotechnology Arrowhead Pharmaceuticals

Companies built like this

Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen MediciNova PRG Science & Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.